News

Filter

Current filters:

Oncologyolaparib

1 to 9 of 14 results

AstraZeneca’s Lynparza backed for approval by EMA committee

AstraZeneca’s Lynparza backed for approval by EMA committee

24-10-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…

AstraZenecaEuropeLynparzaolaparibOncologyPharmaceuticalRegulation

Negative view from FDA advisory for AstraZeneca’s olaparib

Negative view from FDA advisory for AstraZeneca’s olaparib

26-06-2014

There was disappointment for Anglo-Swedish pharma major AstraZeneca yesterday when a US Food and Drug…

AstraZenecaLynparzaolaparibOncologyPharmaceuticalRegulationUSA

Improved overall survival and delayed disease progression influence oncologists in ovarian cancer

Improved overall survival and delayed disease progression influence oncologists in ovarian cancer

06-06-2014

Delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced…

nintedanibolaparibOncologyParaplatinPharmaceuticalResearchTaxolTreatment of advanced ovarian cancerUSA

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

01-06-2014

The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) began on Friday in Chicago,…

AstraZenecaBiotechnologyCyramzaEisaiEli LillylenvatinibolaparibOncologyRecentinResearch

US FDA grants priority review for AstraZeneca’s olaparib

US FDA grants priority review for AstraZeneca’s olaparib

30-04-2014

The US Food and Drug Administration has granted Priority Review for Anglo-Swedish drug major AstraZeneca’s…

AstraZenecaolaparibOncologyPharmaceuticalRegulationUK

Olaparib-resistant ovarian cancer patients live longer also treated with chemotherapy

Olaparib-resistant ovarian cancer patients live longer also treated with chemotherapy

11-10-2013

Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem…

AstraZenecaEuropeolaparibOncologyPharmaceuticalResearch

AstraZeneca's starts olaparib in Ph III for ovarian cancer

04-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has enrolled the first patient in the Phase III…

AstraZenecaMarkets & MarketingMyriad GeneticsolaparibOncologyPharmaceuticalResearch

AstraZeneca in oncology partnerships with University of Cambridge, Cancer Research UK and Blackfield

09-07-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reached agreement with the University of Cambridge…

AstraZenecaBlackfieldBoehringer IngelheimJanssenMerck KGaAolaparibOncologyPharmaceuticalResearch

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top